Redeye is positive about the news that the FDA has approved ISAB’s proposal for a research study aiming to validate the in vitro lung simulation model DissolvIt as an FDA-recommended dissolution technology. The approval includes support and co-financing of the study with up to USD 250,000 annually for up to two years. Our long-term view of ISAB is positive, and we reiterate our Base Case of SEK 23.